ArticleCureus2025
Clinical and Immunologic Manifestations of Antiphospholipid Syndrome Among Patients in King Abdulaziz Medical City (KAMC), Jeddah, Saudi Arabia.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Antiphospholipid syndrome (APS) is a systemic autoimmune disorder marked by the presence of antiphospholipid antibodies (aPL), contributing to a heightened thrombotic risk and complications in pregnancy. This study explores the clinical and immunologic features of APS among patients at King Abdulaziz Medical City (KAMC) in Jeddah, Saudi Arabia, aiming to fill gaps in local APS data and enhance disease profiling. Methods A cross-sectional chart review was conducted for APS patients at KAMC from January 2008 to April 2023. Patients meeting the American College of Rheumatology (ACR) and European Alliance of Associations for Rheumatology (EULAR) APS criteria were included. Clinical manifestations, pregnancy-related complications, and immunologic profiles were documented, and gender differences were statistically analyzed. Results Eighty-eight patients were included, with a female predominance (76.1%). Deep vein thrombosis (35.2%) and recurrent miscarriages (33.0%) were the leading clinical manifestations in males and females, respectively. Stroke and pulmonary embolism were also prevalent, reported in 23.9% each. Anti-cardiolipin antibodies were the most common immunologic marker (56.8%), with a significant gender-based difference favoring males (76.2% vs. 50.7%). Notably, the prevalence of multiple aPL positivity was 31.8%, which was higher among males (42.9%) than females (28.4%), without statistical significance. Conclusion This study contributes essential epidemiological data on APS in Saudi Arabia, emphasizing gender differences and clinical heterogeneity. The findings align with other local studies, indicating younger age of onset in the Saudi population and unique gender-specific differences. High-risk APS patients, particularly males, show a higher risk of thrombosis, warranting personalized preventive strategies. These results underscore the need for tailored APS management, supporting future research to optimize APS care in this region.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.